j
treanor
see
front
matter
elsevi
scienc
bv
right
reserv
pii
first
seri
two
articl
deal
viral
infect
import
elderli
popul
respiratori
viral
infect
long
recogn
import
contributor
death
disabl
older
adult
specif
reason
infecti
agent
usual
caus
selflimit
diseas
healthi
young
adult
associ
enhanc
diseas
age
complet
known
analysi
problem
complic
difficulti
separ
effect
age
chronic
diseas
often
accompani
age
howev
limit
physiolog
reserv
age
potenti
blunt
immun
respons
may
play
role
influenza
viru
tradit
receiv
greatest
attent
remain
signific
problem
age
popul
respiratori
syncyti
viru
parainfluenza
virus
also
implic
potenti
caus
seriou
ill
elderli
individu
brief
review
diseas
impact
infect
influenza
respiratori
syncyti
parainfluenza
virus
review
approach
control
agent
outlin
influenza
uniqu
among
respiratori
virus
epidem
regularli
associ
excess
morbid
mortal
glezen
manifest
excess
rate
pneumonia
influenza
associ
hospit
influenza
epidem
glezen
perrotta
et
al
older
individu
yearli
estim
million
excess
respiratori
ill
associ
influenza
year
recent
nonpandem
influenza
season
associ
averag
excess
pneumonia
influenza
death
allcaus
excess
death
usa
simonsen
et
al
influenza
b
associ
sever
ill
blain
et
al
although
highest
mortal
rate
gener
seen
year
signific
viru
activ
complic
death
influenza
particular
concern
certain
highrisk
medic
condit
primarili
elderli
adult
children
cardiovascular
pulmonari
condit
barker
mullooli
presenc
condit
significantli
increas
risk
influenzarel
hospit
associ
age
alon
barker
mullooli
tabl
although
onefourth
hospit
influenza
occur
individu
age
threefourth
influenzarel
death
occur
age
group
perrotta
et
al
import
recogn
major
elderli
highrisk
individu
hospit
influenza
epidem
ambulatori
lead
product
live
prior
acut
ill
barker
mullooli
addit
caus
seriou
ill
death
influenza
elderli
result
signific
decreas
function
abil
recent
studi
individu
admit
hospit
acut
respiratori
diseas
requir
higher
level
assist
daili
live
requir
prior
ill
gladman
et
al
falsey
et
al
one
nurs
home
outbreak
surviv
acut
influenza
experienc
signific
declin
function
statu
barker
et
al
effect
measur
current
avail
control
influenza
annual
administr
inactiv
influenza
vaccin
vaccin
welltoler
increas
hemagglutin
inhibit
hai
antibodi
seen
young
adult
recipi
cate
et
al
lamontagn
et
al
quinnan
et
al
inactiv
influenza
vaccin
shown
effect
prevent
influenza
sever
control
studi
conduct
young
adult
level
protect
good
antigen
match
vaccin
epidem
virus
meiklejohn
et
al
meiklejohn
ruben
rel
prospect
trial
protect
efficaci
conduct
elderli
popul
one
recent
random
placebocontrol
trial
inactiv
vaccin
approxim
effect
prevent
laboratorydocu
influenza
otherwis
healthi
elderli
popul
fig
govaert
et
al
addit
retrospect
casecontrol
studi
document
effect
inactiv
influenza
vaccin
elderli
exampl
studi
barker
mulooli
document
reduct
hospit
reduct
mortal
influenza
vaccin
elderli
barker
mullooli
recent
metaanalysi
cohort
observ
studi
result
pool
estim
effi
govaert
et
al
caci
vaccin
prevent
influenzarel
respiratori
ill
prevent
pneumonia
prevent
hospit
prevent
death
gross
et
al
vaccin
effect
prevent
pneumonia
influenzarel
hospit
death
effect
prevent
death
caus
influenza
outbreak
period
noninstitution
person
older
manitoba
fedson
et
al
estim
among
elderli
person
live
commun
influenza
vaccin
associ
direct
save
per
year
per
person
vaccin
nichol
et
al
howev
protect
efficaci
vaccin
appear
lower
individu
age
younger
adult
explan
decreas
efficaci
elderli
complet
clear
least
part
relat
decreas
antibodi
respons
influenza
vaccin
age
group
cole
et
al
nicholson
et
al
power
belsh
remarqu
et
al
treanor
et
al
exampl
antibodi
respons
inactiv
influenza
vaccin
two
group
elderli
subject
individu
live
independ
home
resid
chronic
care
facil
compar
respons
healthi
adult
tabl
unpublish
studi
addit
level
antibodi
associ
need
protect
influenza
ill
elderli
may
higher
titer
tradit
associ
protect
young
adult
bennett
et
al
bett
et
al
studi
shown
diminish
respons
influenza
vaccin
elderli
affect
specif
antigen
occasion
outweigh
effect
age
glath
et
al
effect
age
may
primarili
effect
subclass
haspecif
igg
produc
power
consist
affect
age
number
naiv
cell
studi
presenc
chronic
disabl
rather
age
subject
appear
better
abl
predict
lack
respons
gross
et
al
malnutrit
identifi
common
problem
disabl
elderli
appear
contribut
reduc
respons
vaccin
peopl
pozzetto
et
al
effort
improv
perform
influenza
vaccin
elderli
focus
three
basic
area
improv
level
dura
tion
system
immun
respons
vaccin
improv
mucos
immun
respons
addit
cellular
immun
respons
spectrum
potenti
protect
respons
induc
vaccin
howev
two
featur
current
inactiv
vaccin
import
keep
mind
consid
new
approach
influenza
prevent
popul
first
current
vaccin
welltoler
signific
increas
local
system
sideeffect
seen
current
vaccin
would
like
accept
poorli
second
current
vaccin
rel
inexpens
improv
efficaci
might
support
modest
increas
cost
high
dose
current
vaccin
administ
standard
dose
mg
ha
per
antigen
recent
improv
purif
techniqu
allow
explor
much
higher
dose
vaccin
administr
mg
highli
purifi
monoval
antigen
healthi
young
adult
trival
vaccin
contain
mg
antigen
welltoler
produc
higher
geometr
mean
serum
hai
neutral
antibodi
titer
week
vaccin
compar
standard
dose
keitel
et
al
improv
nasal
secret
antibodi
respons
high
dose
vaccin
also
seen
keitel
et
al
studi
high
dose
vaccin
elderli
subject
gener
demonstr
less
robust
doserespons
curv
seen
young
adult
gross
et
al
palach
et
al
evalu
high
dose
recombin
ha
express
baculoviru
reach
similar
conclus
dose
mg
ha
result
significantli
increas
postimmun
antibodi
titer
young
adult
compar
standard
inactiv
vaccin
howev
dose
respons
curv
flat
elderli
recipi
littl
increas
even
mg
compar
standard
vaccin
enhanc
protect
efficaci
result
use
high
dose
ha
popul
remain
evalu
commonli
use
adjuv
vaccin
human
alum
aluminum
hydroxid
aluminum
phosphat
alum
adsorb
ha
influenza
virus
effici
alum
adjuv
use
inactiv
influenza
vaccin
adjuv
evalu
influenza
vaccin
anim
phase
studi
consist
agent
modifi
immun
respons
directli
squalen
deriv
monophosphoryl
lipid
mpl
purifi
soapbark
deriv
quil
dihydroepiandosteron
dhea
dayn
araneo
cytokin
anoth
strategi
physic
modifi
vaccin
improv
antigen
present
formul
liposom
el
guink
et
al
kaji
et
al
multimer
complex
iscom
immunostimul
complex
sundquist
et
al
lovgren
et
al
sever
studi
perform
elderli
human
compar
respons
adjuv
nonadjuv
formul
inactiv
influenza
vaccin
studi
shown
enhanc
serum
antibodi
respons
singl
formul
emerg
clearli
superior
inactiv
influenza
vaccin
formul
fluad
chiron
vaccin
result
slightli
higher
level
postimmun
antibodi
elderli
recipi
compar
nonadjuv
vaccin
expens
higher
rate
mild
local
system
sideeffect
martin
minutello
et
al
vaccin
formul
licens
itali
dehydroepiandrosteron
dhea
report
increas
postvaccin
antibodi
titer
elderli
subject
primarili
without
histori
previou
vaccin
benyehuda
et
al
liposom
inactiv
vaccin
welltoler
induc
frequent
ctl
respons
enhanc
antibodi
respons
vaccin
small
studi
elderli
subject
power
contrast
virosom
prepar
incorpor
liposom
phosphatidylcholin
phosphatidylethanolamin
result
enhanc
antibodi
respons
elderli
subject
gluck
et
al
licens
switzerland
conjug
hemagluttinin
protein
carrier
report
enhanc
immun
respons
protect
efficaci
gravenstein
et
al
use
thymosinalpha
improv
antibodi
respons
elderli
men
gravenstein
et
al
cytokin
provinciali
et
al
addit
potenti
adjuv
describ
like
improv
forthcom
studi
varieti
anim
model
confirm
import
mucos
immun
protect
influenza
renegar
small
limit
studi
human
also
suggest
effect
protect
immun
induc
influenza
viru
infect
mediat
predominantli
local
haspecif
iga
clement
et
al
b
thu
method
induc
mucos
immun
attract
option
improv
influenza
vaccin
perform
live
attenu
influenza
viru
vaccin
gener
genet
reassort
coldadapt
influenza
b
virus
maassab
debord
extens
evalu
children
young
adult
elderli
subject
review
murphi
safeti
also
demonstr
highrisk
individu
would
abl
toler
even
minor
lower
respiratori
tract
inflamm
individu
cystic
fibrosi
asthma
miyazaki
et
al
gruber
et
al
adult
coldadapt
vaccin
gener
effect
parenter
administ
inactiv
influenza
vaccin
induc
nasal
haspecif
iga
induc
level
serum
hai
haspecif
igg
antibodi
slightli
lower
seen
inactiv
vaccin
although
studi
extens
limit
data
suggest
coldadapt
influenza
vaccin
may
also
induc
antibodi
cytotox
cell
broaden
recognit
within
subtyp
seen
inactiv
vaccin
gors
belsh
clover
et
al
field
trial
evalu
demonstr
protect
efficaci
ca
reassort
influenza
vaccin
children
adult
recent
complet
field
trial
children
age
month
demonstr
greater
efficaci
trival
coldadapt
influenza
vaccin
prevent
cultur
posit
influenza
influenza
b
belsh
et
al
adult
random
doubleblind
trial
conduct
individu
year
show
monoor
bival
coldadapt
vaccin
approxim
equal
inactiv
vaccin
prevent
laboratori
confirm
influenza
ill
edward
et
al
trival
formul
coldadapt
vaccin
flumist
approxim
equal
effect
inactiv
vaccin
prevent
infectionassoci
ill
due
three
compon
experiment
infect
adult
recent
studi
flumist
effect
prevent
febril
upper
respiratori
tract
ill
influenza
season
popul
work
adult
nichol
et
al
live
attenu
coldadapt
influenza
vaccin
thu
repres
promis
approach
influenza
vaccin
studi
coldadapt
vaccin
elderli
highrisk
subject
shown
vaccin
welltoler
popul
also
gors
et
al
gors
et
al
power
et
al
atmar
et
al
gors
belsh
power
et
al
power
et
al
chang
oxygen
satur
pulmonari
mechan
seen
coldadapt
vaccin
given
elderli
subject
chronic
lung
diseas
gors
et
al
gors
et
al
atmar
et
al
minor
vaccin
recipi
shed
detect
viru
nasal
secret
gener
low
titer
short
durat
serum
antibodi
respons
coldadapt
vaccin
elderli
subject
less
seen
younger
subject
gors
et
al
gors
et
al
power
et
al
power
et
al
power
et
al
system
antibodi
respons
coldadapt
influenza
viru
vaccin
measur
hemagglutininspecif
igg
enzym
immunoassay
variou
type
observ
subject
significantli
less
rate
system
antibodi
respons
inactiv
vaccin
studi
addit
geometr
mean
serum
antibodi
titer
higher
follow
inactiv
influenza
vaccin
coldadapt
vaccin
local
haspecif
iga
respons
seen
elderli
recipi
coldadapt
vaccin
slightli
lower
rate
local
antibodi
respons
seen
follow
inactiv
vaccin
mean
postvaccin
nasal
antibodi
level
often
difficult
interpret
high
degre
variabl
level
preimmun
antibodi
inher
difficulti
make
type
measur
appear
somewhat
higher
receiv
coldrecombin
vaccin
rel
less
work
perform
evalu
coldadapt
influenza
b
viru
vaccin
elderli
howev
one
studi
ambulatori
elderli
adult
demonstr
coldadapt
influenza
b
viru
vaccin
welltoler
less
immunogen
inactiv
vaccin
treanor
et
al
nasal
wash
antibodi
respons
seen
frequent
vaccin
given
studi
reason
appar
decreas
infect
coldadapt
influenza
vaccin
virus
elderli
may
relat
extens
previou
exposur
older
adult
influenza
viru
infect
howev
immunolog
experi
simpli
reflect
serum
hai
titer
infect
coldrecombin
vaccin
older
adult
low
even
low
prevaccin
serum
hai
antibodi
titer
power
et
al
studi
elderli
adult
prevaccin
serum
hi
titer
respond
vaccin
cr
viru
compar
young
adult
power
et
al
rel
lack
serum
hai
antibodi
respons
vaccin
coldadapt
influenza
vaccin
older
adult
suggest
vaccin
may
optim
use
alon
popul
howev
live
vaccin
appear
potenti
offer
benefit
induct
frequent
local
antibodi
respons
seen
inactiv
vaccin
led
hypothesi
use
vaccin
might
synergist
effect
inactiv
vaccin
provid
system
immun
coldadapt
vaccin
augment
local
immun
respons
preliminari
evalu
immunogen
parenter
inactiv
vaccin
given
intranas
coldadapt
vaccin
suggest
combin
live
inactiv
vaccin
result
modest
consist
increas
frequenc
immun
respons
compar
either
inactiv
vaccin
coldadapt
vaccin
alon
power
et
al
power
et
al
gors
et
al
treanor
bett
promis
result
basi
small
field
trial
evalu
combin
intranas
coldadapt
vaccin
intramuscular
inactiv
influenza
vaccin
prevent
influenza
resid
nurs
home
treanor
et
al
particip
receiv
trival
inactiv
influenza
vaccin
parenter
randomli
assign
receiv
either
live
attenu
influenza
vaccin
placebo
intranas
influenza
activ
rel
quiescent
studi
attack
rate
influenza
particip
nurs
home
gener
low
howev
period
studi
particip
receiv
intranas
vaccin
subsequ
expos
influenza
significantli
lower
rate
laboratorydocu
influenza
outbreak
associ
ie
tempor
relat
institut
influenza
outbreak
respiratori
ill
fig
treanor
et
al
similar
studi
compar
intramuscular
trival
inactiv
vaccin
combin
intranas
coldadapt
influenza
b
inactiv
vaccin
alon
also
show
reduct
laboratorydocu
influenza
b
combin
vaccin
rate
infect
low
allow
conclus
drawn
efficaci
approach
influenza
b
treanor
bett
summari
current
avail
data
suggest
coldadapt
influenza
vaccin
safe
elderli
chronic
ill
individu
local
system
antibodi
respons
clearli
less
seen
young
adult
even
elderli
individu
rel
low
prevaccin
serum
hai
titer
addit
system
antibodi
respons
coldadapt
vaccin
gener
less
frequent
lower
magnitud
seen
inactiv
vaccin
local
antibodi
respons
margin
greater
howev
combin
intranas
coldadapt
intramuscular
inactiv
vaccin
provid
significantli
greater
protect
popul
inactiv
vaccin
alon
despit
modest
appar
increas
immunogen
data
promis
confirm
larger
popul
period
signific
influenza
activ
channel
inhibitor
antivir
drug
amantadin
rimantadin
licens
usa
countri
treatment
prevent
influenza
adult
drug
act
inhibit
action
viral
protein
ion
channel
play
import
role
viral
uncoat
influenza
virus
contain
protein
interact
drug
amantadin
rimantadin
activ
influenza
virus
studi
demonstr
efficaci
channel
inhibitor
acut
influenza
larg
carri
younger
adult
popul
children
studi
demonstr
therapi
within
h
onset
symptom
associ
reduct
symptom
score
rapid
resolut
fever
return
normal
activ
studi
reduct
viral
shed
van
vori
et
al
younkin
et
al
hayden
monto
efficaci
demonstr
infect
due
influenza
virus
neither
drug
subject
extens
efficaci
evalu
highrisk
subject
one
placebocontrol
blind
studi
carri
nurs
home
patient
show
rapid
reduct
fever
symptom
rimantadin
recipi
furthermor
physician
care
patient
blind
studi
drug
statu
prescrib
significantli
fewer
antipyret
antituss
antibiot
obtain
fewer
chest
xray
rimantadin
recipi
bett
et
al
effect
earli
therapi
highrisk
individu
amantadin
rimantadin
reduc
frequenc
subsequ
complic
unknown
channel
inhibitor
also
effect
prevent
influenza
largescal
studi
season
prophylaxi
otherwis
healthi
adult
drug
efficaci
rate
laboratorydocu
influenza
dolin
et
al
dougla
amantadin
rimantadin
similar
level
efficaci
set
rimantadin
associ
significantli
fewer
sideeffect
dolin
et
al
efficaci
also
demonstr
postexposur
prophylaxi
famili
set
galbraith
fig
rate
laboratorydocu
influenza
ill
outbreakassoci
respiratori
ill
outbreakassoci
influenzalik
ill
nurs
home
resid
random
receiv
parenter
inactiv
influenza
vaccin
intranas
coldadapt
influenza
vaccin
intranas
placebo
treanor
et
al
treanor
et
al
et
al
find
suggest
prophylaxi
contact
close
set
nurs
home
would
also
effect
termin
influenza
outbreak
evid
effect
outbreakiniti
prophylaxi
nurs
home
larg
observ
suggest
earli
initi
reduc
rate
influenza
institut
atkinson
et
al
arden
et
al
use
prophylaxi
day
effect
longer
cours
administr
drinka
et
al
current
recommend
institut
outbreak
influenza
occur
chemoprophylaxi
administ
resid
continu
approxim
week
week
termin
outbreak
cdc
develop
antivir
resist
treat
individu
subsequ
transmiss
contact
significantli
limit
effect
postexposur
prophylaxi
either
famili
set
hayden
et
al
institut
mast
et
al
degelau
et
al
reason
recommend
treat
prophylax
individu
isol
possibl
cdc
howev
resist
influenza
viru
identifi
set
even
onset
amantadin
rimantadin
administr
houck
et
al
amantadin
rimantadin
administ
maximum
dose
mg
per
day
individu
age
daili
dose
amantadin
may
need
reduc
individu
impair
renal
function
mg
per
day
incid
cn
sideeffect
elderli
substanti
lower
rimantadin
amantadin
keyser
et
al
howev
sideeffect
rimantadin
elderli
occur
higher
rate
young
adult
tominack
hayden
administr
amantadin
individu
motor
seizur
report
increas
frequenc
seizur
atkinson
et
al
may
also
occur
rimantadin
appear
less
frequent
soo
one
studi
longterm
prophylact
administr
rimantadin
nurs
home
popul
welltoler
estim
efficaci
prevent
flu
nurs
home
monto
et
al
neuraminidas
inhibitor
determin
crystal
structur
neuraminidas
complex
sialic
acid
varghes
et
al
allow
develop
seri
analog
neuraminidaseinhibit
activ
von
itzstein
et
al
first
compound
evalu
clinic
studi
acid
zanamivir
relenza
highli
potent
select
inhibitor
neuraminidas
influenza
b
virus
zanamivir
signific
antivir
activ
wide
varieti
laboratori
clinic
influenza
b
isol
cell
cultur
mous
ferret
model
von
itzstein
et
al
wood
et
al
drug
oral
bioavail
administ
topic
intranas
zanamivir
effect
therapi
influenza
experiment
infect
adult
volunt
earli
treatment
begin
h
challeng
late
treatment
begin
h
challeng
effect
reduc
viru
shed
compar
placebo
earli
treatment
also
reduc
symptom
score
reduc
frequenc
middl
ear
abnorm
hayden
et
al
walker
et
al
subsequ
inhal
zanamivir
shown
effect
earli
treatment
natur
acquir
acut
influenza
b
man
result
approxim
decreas
durat
symptom
administ
within
first
h
ill
zanamivir
also
reduc
frequenc
complic
small
number
highrisk
subject
mist
drug
thu
repres
first
antivir
clearcut
clinic
efficaci
influenza
b
man
zanamivir
recent
licens
treatment
acut
uncompl
influenza
adult
oral
antineuraminidas
inhibitor
oseltamivir
tamiflu
develop
also
demonstr
therapeut
efficaci
experiment
infect
adult
hayden
et
al
rel
less
inform
avail
regard
use
zanamivir
prophylaxi
one
studi
daili
zanamivir
inhal
associ
reduct
influenza
ill
healthi
adult
epidem
season
monto
et
al
use
elderli
evalu
extens
one
small
studi
nurs
home
experienc
sequenti
outbreak
influenza
b
use
outbreakiniti
prophylaxi
either
rimantadin
zanamivir
compar
influenza
outbreak
zanamivir
treatment
influenza
b
outbreak
one
case
laboratori
confirm
influenza
influenza
occur
studi
subject
individu
receiv
rimantadin
one
case
influenza
b
individu
receiv
treatment
respiratori
syncyti
viru
rsv
one
import
caus
lower
respiratori
tract
infect
infant
young
children
caus
estim
hospit
death
annual
usa
glezen
et
al
mufson
et
al
parrott
et
al
immun
rsv
incomplet
reinfect
occur
throughout
life
although
reinfect
alway
consid
mild
ill
hall
et
al
hall
et
al
tradit
sever
rsv
infect
consid
problem
childhood
howev
rsv
recent
identifi
common
caus
seriou
diseas
number
adult
popul
includ
immunocompromis
person
frail
elderli
underli
cardiopulmonari
diseas
englund
et
al
englund
et
al
martin
et
al
hertz
et
al
falsey
et
al
falsey
et
al
harrington
et
al
whimbey
et
al
despit
recent
advanc
understand
rsv
infect
infant
three
import
area
regard
rsv
infect
adult
remain
rel
unexplor
includ
detail
knowledg
epidemiolog
clinic
impact
rsv
variou
adult
popul
understand
mechan
diseas
pathogenesi
develop
correl
immun
rsv
adult
among
elderli
adult
rsv
signific
caus
excess
morbid
mortal
rsv
infect
document
attende
senior
daycar
center
communitydwel
institution
elderli
falsey
et
al
falsey
et
al
rsv
outbreak
welldocu
nurs
home
attack
rate
rang
mathur
et
al
sorvillo
et
al
agiu
et
al
falsey
et
al
howev
also
note
rsv
consist
identifi
winter
caus
sporad
respiratori
ill
nurs
home
indic
rsv
infect
limit
nosocomi
outbreak
osterweil
et
al
falsey
et
al
even
document
influenza
viru
epidem
rsv
infect
identifi
popul
falsey
et
al
one
surveil
studi
nurs
home
rochest
new
york
rsv
caus
acut
respiratori
tract
infect
singl
winter
season
falsey
et
al
studi
rhinoviru
parainfluenza
virus
next
commonli
identifi
agent
rsv
infect
patient
four
develop
pneumonia
two
die
sever
rsv
infect
institution
person
quit
variabl
seriou
complic
wellrecogn
rate
pneumonia
rang
mortal
mathur
et
al
sorvillo
et
al
agiu
et
al
falsey
et
al
falsey
et
al
symptom
often
indistinguish
influenza
viru
infect
although
presenc
nasal
congest
wheez
characterist
rsv
mathur
et
al
addit
institution
elderli
rsv
also
recov
attende
adult
day
care
center
falsey
et
al
period
encompass
two
winter
season
rochest
ny
rsv
identifi
particip
slightli
less
influenza
b
viru
infect
occur
period
although
death
directli
attribut
rsv
one
infect
patient
requir
hospit
pneumonia
littl
inform
avail
incid
rsv
infect
commun
dwell
elderli
although
signific
ill
clearli
occur
winter
three
case
cultur
posit
rsv
lower
respiratori
tract
infect
identifi
one
analysi
commun
acquir
pneumonia
zaroukian
et
al
case
report
among
elderli
patient
averag
age
retrospect
review
hospit
pneumonia
sweden
repres
pneumonia
case
vikerfor
et
al
vikerfor
et
al
rochest
ny
admiss
person
year
age
older
acut
cardiopulmonari
flulik
ill
period
caus
rsv
due
influenza
viru
falsey
et
al
underli
copd
congest
heart
failur
present
rsv
infect
patient
respect
mortal
among
rsv
infect
patient
compar
mortal
influenza
viru
infect
patient
discharg
higher
level
care
among
hospit
adult
ohio
rsv
third
common
identifi
caus
behind
streptococcu
pneumonia
influenza
viru
dowel
et
al
rsv
case
year
age
slightli
half
underli
copd
coronari
arteri
diseas
congest
heart
failur
addit
clinic
report
describ
acut
lower
respiratori
tract
infect
grow
evid
implic
rsv
import
contributor
excess
morbid
within
geriatr
popul
winter
shown
influenza
viru
although
impact
rsv
elderli
less
readili
appar
infant
evid
continu
accumul
among
communitydwel
older
person
rsv
may
seriou
nonpandem
influenza
nicholson
et
al
fleme
et
al
unit
kingdom
excess
mortal
older
person
tempor
associ
peak
rsv
activ
children
fleme
et
al
detail
statist
analysi
data
span
also
uk
rsv
greater
impact
influenza
viru
excess
morbid
mortal
person
age
nicholson
et
al
littl
known
immun
diseas
pathogenesi
elderli
highrisk
adult
known
increas
sever
rsv
infect
age
group
result
underli
frailti
host
global
immunosenesc
age
relat
declin
one
anoth
rsvspecif
immun
function
littl
known
role
antibodi
rsv
elderli
except
adult
detect
serum
antibodi
falsey
et
al
elderli
adult
capabl
mount
brisk
serum
iga
igg
respons
rsv
infect
angiu
et
al
import
rel
lack
serum
neutral
antibodi
recent
found
risk
factor
rsv
diseas
studi
frail
elderli
adult
falsey
et
al
baselin
blood
sampl
obtain
subject
attend
senior
daycar
center
volunt
follow
next
month
evalu
acut
respiratori
tract
ill
sampl
subject
develop
symptomat
rsv
infect
compar
control
subject
becom
infect
rsv
mean
serum
igg
titer
rsv
fusion
protein
f
significantli
lower
rsvinfect
group
compar
control
neutral
titer
group
rsv
fig
data
suggest
older
adult
low
level
serum
neutral
antibodi
may
greater
risk
develop
symptomat
rsv
support
view
boost
titer
vaccin
may
benefici
current
sever
rsv
vaccin
candid
human
trial
potenti
develop
numer
addit
vaccin
candid
one
approach
potenti
benefit
elderli
use
purifi
rsv
f
protein
wyethlederl
vaccin
result
previous
infect
children
vaccin
demonstr
stimul
neutral
antibodi
group
b
strain
although
largescal
efficaci
studi
perform
belsh
et
al
also
safe
reason
immunogen
healthi
frail
elderli
subject
twentynin
healthi
elderli
recipi
vaccin
greater
rise
serum
igg
f
protein
week
postvaccin
twenti
greater
rise
serum
neutral
titer
group
group
b
rsv
studi
fig
preill
level
serum
neutral
antibodi
group
rsv
elderli
individu
enrol
adult
day
care
subsequ
infect
rsv
rsv
outbreak
falsey
et
al
respons
vaccin
invers
correl
preimmun
serum
neutral
titer
subject
follow
throughout
ensu
winter
rsv
infect
identifi
placebo
group
none
vaccin
group
falsey
walsh
second
studi
evalu
institution
person
age
falsey
walsh
vaccin
welltoler
subject
complet
studi
nineteen
vaccine
greater
rise
igg
f
protein
week
signific
rise
neutral
titer
either
group
b
viru
respons
rate
correl
preimmun
neutral
titer
although
appear
slightli
less
immunogen
institution
elderli
healthi
elderli
recent
anim
studi
suggest
adjuv
mpl
monophosphoryl
lipid
alter
primari
immun
respons
fg
toward
pattern
rather
pattern
seen
alum
use
adjuv
neuzil
et
al
vaccin
could
potenti
induc
greater
neutral
antibodi
titer
f
protein
vaccin
due
induct
antibodi
g
protein
incorpor
specif
rsv
gene
notabl
f
viru
vector
vaccinia
viru
adenoviru
success
complet
could
use
vaccin
although
promis
rodent
vaccin
reach
clinic
trial
infant
lack
immunogen
efficaci
subhuman
primat
wertz
et
al
hsu
et
al
hsu
et
al
howev
possibl
alreadi
prime
elderli
subject
vector
vaccin
may
immunogen
live
attenu
vaccin
repres
attract
approach
toward
develop
rsv
vaccin
restimul
local
nasal
immun
balanc
cellular
immun
respons
initi
result
temperaturesensit
ts
coldadapt
ca
mutant
disappoint
infant
vaccin
either
poorli
immunogen
excess
virul
genet
unstabl
wright
et
al
current
sever
new
live
viru
vaccin
evalu
infant
genet
stabl
attenu
virus
produc
previou
cold
passag
temperaturesensit
cpt
mutant
addit
chemic
mutagenesi
precis
genet
alter
defin
sequenc
analysi
viral
rna
crow
et
al
fireston
et
al
viru
one
sever
candid
temperaturesensit
vaccin
shutoff
temperatur
studi
rodent
chimpanze
show
viru
phenotyp
stabl
despit
restrict
replic
immunogen
protect
wildtyp
challeng
crow
et
al
anoth
live
viru
vaccin
candid
produc
chemic
mutagenesi
mckay
et
al
pringl
et
al
viru
replic
shut
studi
adult
volunt
vaccin
found
stabl
attenu
modestli
immunogen
recent
develop
full
length
infecti
cdna
clone
rsv
produc
live
viru
upon
transfect
cell
tissu
cultur
offer
potenti
limitless
suppli
specif
alter
live
vaccin
product
collin
et
al
parainfluenza
virus
common
caus
respiratori
tract
ill
infant
young
children
although
serotyp
distinct
epidemiolog
clinic
characterist
individu
case
gener
possibl
distinguish
virus
although
epidemiolog
piv
infect
rel
constant
nation
level
substanti
region
variat
distribut
serogroup
year
chanock
mcintosh
virus
caus
wide
spectrum
diseas
mild
upper
respiratori
symptom
life
threaten
pneumonia
tend
occur
fall
everi
year
associ
half
croup
case
also
caus
bronchiol
pneumonia
like
may
occur
everi
year
although
also
seen
annual
associ
croup
infect
occur
age
although
sever
diseas
uncommon
age
year
children
demonstr
serolog
evid
infect
age
year
contrast
tend
infect
infant
less
month
age
half
infant
infect
first
year
life
rest
infect
age
year
specif
associ
croup
second
rsv
caus
bronchiol
pneumonia
young
infant
viru
endem
infect
occur
throughout
year
includ
winter
spring
summer
month
although
gener
consid
diseas
childhood
parainfluenza
virus
like
rsv
recent
recogn
caus
seriou
respiratori
ill
certain
adult
popul
elderli
sever
immunocompromis
parainfluenza
infect
adult
alway
repres
reinfect
gener
symptom
limit
upper
respiratori
tract
produc
mild
lower
tract
symptom
cooney
et
al
within
famili
young
adult
parent
develop
evid
infect
parainfluenza
viru
introduc
household
cooney
et
al
piv
infect
document
commun
dwell
elderli
pneumonia
sign
lower
respiratori
tract
infect
mufson
et
al
fransen
et
al
cooney
et
al
stanek
heinz
greenberg
monto
sullivan
howev
incid
clinic
signific
piv
group
appear
variabl
one
report
commun
acquir
piv
lower
respiratori
tract
infect
isol
two
patient
document
seroconvers
piv
subject
mufson
et
al
person
year
age
seroconvers
piv
associ
lower
respiratori
tract
ill
respect
contrast
rate
control
without
respiratori
symptom
anoth
serolog
studi
respiratori
ill
sweden
case
piv
infect
detect
patient
pneumonia
fransen
et
al
patient
greater
year
age
serolog
evid
piv
infect
recent
piv
infect
identifi
acut
respiratori
ill
person
age
year
year
commun
surveil
tecumseh
mi
comparison
influenza
b
virus
identifi
caus
ill
howev
investig
describ
parainfluenza
viru
caus
lower
respiratori
tract
ill
adult
cooney
et
al
macfarlan
et
al
marri
et
al
outbreak
parainfluenza
type
also
report
longterm
care
facil
anon
ill
character
fever
sore
throat
rhinorrhea
cough
rate
pneumonia
high
sever
death
attack
rate
resid
employe
respect
note
alabama
nurs
home
outbreak
prospect
studi
nurs
home
popul
parainfluenza
virus
respons
respiratori
ill
arroyo
et
al
gross
et
al
falsey
et
al
falsey
et
al
parainfluenza
viru
also
implic
caus
exacerb
chronic
obstruct
pulmonari
diseas
copd
carilli
et
al
buscho
et
al
hudgel
et
al
smith
et
al
composit
piv
gener
second
third
behind
influenza
viru
respiratori
syncyti
viru
caus
acut
deterior
lung
function
group
fagan
chastr
earliest
attempt
immun
piv
use
formalin
inactiv
trival
whole
viru
vaccin
fulgin
et
al
weibel
et
al
fulgin
et
al
although
immunogen
efficaci
infant
thu
abandon
howev
contrast
find
inactiv
rsv
vaccin
discuss
evid
enhanc
diseas
infant
receiv
piv
vaccin
purifi
hn
f
viru
vector
express
hn
f
provid
materi
either
parenter
topic
immun
test
anim
model
parainfluenza
viru
infect
blain
et
al
ray
et
al
sprigg
et
al
ray
et
al
sullivan
et
al
two
live
attenu
parainfluenza
type
vaccin
also
develop
use
infant
children
karron
et
al
b
one
bovin
piv
signific
antigen
related
human
attenu
primat
base
long
evolut
heterolog
bovin
host
second
coldpassag
cp
coldadapt
ca
temperaturesensit
ts
mutant
js
strain
human
seroneg
children
vaccin
welltoler
highli
immunogen
seroconvers
highest
dose
given
howev
seroposit
children
perhap
predict
perform
vaccin
adult
develop
rise
hemagglutin
titer
develop
nasal
iga
respons
common
cold
one
common
diseas
experi
age
group
although
singl
clinic
entiti
defin
cold
gener
cold
consid
predominantli
respiratori
ill
includ
symptom
rhiniti
variabl
degre
pharyng
gwaltney
et
al
rao
et
al
patient
often
report
chill
true
fever
unusu
cough
hoars
occasion
also
part
ill
lower
respiratori
tract
sign
symptom
characterist
cold
recogn
complic
cold
adult
includ
secondari
bacteri
infect
paranas
sinus
middl
ear
exacerb
asthma
chronic
bronchiti
emphysema
although
mani
viral
etiolog
common
cold
two
virus
often
associ
syndrom
rhinovirus
coronavirus
emerg
potenti
import
pathogen
frail
elderli
rhinovirus
infect
extrem
common
usa
observ
rate
infect
per
person
per
year
adult
gwaltney
et
al
hamr
procknow
usa
rv
infect
preval
earli
fall
late
spring
major
reservoir
rv
school
children
transmit
rv
infect
among
peer
classroom
beem
et
al
introduc
home
infect
famili
member
hendley
et
al
addit
caus
cold
symptom
rhinovirus
implic
develop
acut
sinus
precipit
exacerb
chronic
bronchiti
asthma
viru
recov
aspir
obtain
direct
punctur
maxillari
sinus
patient
acut
sinus
pitkaranta
et
al
mucos
thicken
andor
sinu
exud
observ
mani
subject
acut
cold
turner
et
al
gwaltney
et
al
clinic
manifest
acut
sinus
seen
small
proport
individu
natur
occur
cold
wald
et
al
mani
exacerb
chronic
bronchiti
associ
rv
infect
eadi
et
al
stenhous
mcnamara
et
al
lambert
et
al
howev
effect
rv
infect
pulmonari
function
patient
chronic
obstruct
pulmonari
diseas
less
mark
influenza
infect
smith
et
al
known
whether
rhinoviru
invad
bronchial
tree
directli
sever
studi
indic
direct
invas
may
occur
halperin
et
al
gern
et
al
rhinoviru
also
among
respiratori
virus
shown
precipit
attack
asthma
predominantli
children
minor
et
al
minor
et
al
horn
et
al
also
adult
teichtahl
et
al
experiment
rv
infect
vari
sever
led
develop
wheez
increas
bronchial
reactiv
demonstr
histamin
provoc
adult
mild
moder
asthma
halperin
et
al
coronavirus
moderates
nm
round
virus
contain
positivesens
singlestrand
rna
distinct
clubshap
project
present
viru
surfac
give
viru
particl
appear
crown
corona
deriv
name
two
antigen
type
human
coronaviru
recogn
strain
isol
cell
cultur
human
embryon
lung
cell
fibroblast
strain
requir
organ
cultur
coronaviru
group
also
appear
import
caus
common
cold
although
overal
contribut
annual
respiratori
diseas
morbid
uncertain
longitudin
studi
adult
coronavirus
account
acut
respiratori
diseas
annual
peak
period
hamr
beem
hendley
et
al
annual
ill
rate
children
measur
peak
rate
kay
et
al
kay
dowdl
report
frequenc
infect
adult
virus
rang
per
person
per
year
infect
occur
person
prior
antibodi
infect
viru
cavallaro
monto
hamr
beem
hendley
et
al
monto
lim
larg
peak
coronaviru
activ
occur
winter
earli
spring
infect
detect
throughout
year
macnaughton
monto
recent
data
implic
virus
common
caus
moder
debilit
acut
respiratori
diseas
older
adult
prospect
studi
identifi
rhinovirus
associ
acut
respiratori
ill
elderli
adult
attend
supervis
day
care
mani
onefourth
episod
occur
among
ambulatori
elderli
adult
nicholson
et
al
studi
coronavirus
identifi
respons
episod
respect
rhinoviru
outbreak
also
report
longterm
care
set
falsey
et
al
wald
et
al
strike
featur
ill
signific
lower
respiratori
tract
involv
mani
case
sign
symptom
cough
sputum
product
dyspnea
wheez
report
individu
significantli
common
elderli
younger
health
care
worker
tabl
clinic
ill
caus
coronaviru
rhinoviru
ambulatori
elderli
adult
similar
associ
influenza
nicholson
et
al
associ
signific
mobid
restrict
activ
seen
almost
onefifth
rhinoviru
ill
infect
result
medic
consult
presenc
chronic
medic
condit
smoke
may
risk
factor
develop
lower
respiratori
tract
symptom
rhinoviru
infect
nicholson
et
al
note
howev
rhinoviru
coronaviru
infect
yet
establish
convincingli
caus
increas
level
hospit
admiss
enhanc
mortal
among
elderli
popul
effect
therapi
rv
cold
current
avail
symptomat
treatment
individu
complaint
howev
high
incid
develop
effect
antivir
therapi
rhinoviru
infect
object
consider
interest
mani
year
detail
review
effort
mani
year
gener
treatment
beyond
scope
review
mani
studi
util
experiment
infect
human
adult
volunt
purpos
benefit
seen
model
earli
treatment
combin
interferon
ipratroprium
bromid
given
nasal
naproxen
given
oral
gwaltney
capsid
bind
agent
pirodavir
hayden
et
al
pleconaril
rhinoviru
serotyp
use
cellular
receptor
receptor
blockad
solubl
also
evalu
minor
benefit
turner
et
al
pleconaril
report
reduc
durat
symptom
natur
occur
cold
although
serotypespecif
immun
develop
infect
fleet
et
al
prospect
rhinoviru
vaccin
poor
multipl
rhinoviru
serotyp
antivir
agent
clinic
use
coronaviru
infect
current
unavail
treatment
coronaviru
cold
also
depend
upon
use
symptomat
therapi
intranas
interferon
protect
experiment
coronaviru
cold
higgin
et
al
intranas
nedocromil
sodium
also
effect
reduc
nasal
mucu
weight
model
barrow
et
al
littl
attent
given
develop
coronaviru
vaccin
volunt
experi
infect
coronaviru
induc
effect
shortterm
immun
appear
rechalleng
homotyp
viru
challeng
strain
serotyp
result
infect
ill
reed
viral
respiratori
infect
repres
signific
challeng
interest
improv
health
elderli
influenza
continu
result
larg
burden
excess
morbid
mortal
two
effect
measur
inactiv
influenza
vaccin
antivir
drug
rimantadin
amantadin
current
avail
control
diseas
inactiv
vaccin
given
yearli
age
well
younger
individu
highrisk
medic
condit
individu
deliv
care
person
live
intranas
administ
attenu
influenza
vaccin
also
develop
ment
may
use
combin
inactiv
vaccin
elderli
antivir
drug
amantadin
rimantadin
effect
treatment
prevent
influenza
although
rimantadin
associ
fewer
sideeffect
recent
inhal
neuraminidas
inhibitor
zanamivir
activ
influenza
b
virus
licens
use
uncompl
influenza
role
drug
treatment
prevent
influenza
elderli
remain
determin
addit
neuraminidas
inhibitor
also
develop
addit
influenza
respiratori
infect
respiratori
syncyti
viru
parainfluenza
viru
rhinoviru
coronaviru
identifi
potenti
problem
elderli
increas
attent
probabl
impact
infect
age
group
extens
document
understand
immunolog
pathogenesi
infect
elderli
adult
infanc
consider
addit
work
need
perform
toward
develop
effect
control
measur
